Company profile
Wuhan General Group (China), Inc.
OTC: WUHN · Healthcare · Medical - Pharmaceuticals
PublicHQ Cape Town, NVReports USD
#1131 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 59
v0.1 · 5/100 weight · pillars only
↑ workforce scale, balance-sheet leverage · ↓ operating margin, net margin
Methodology →Revenue TTM
$14.2k
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.7M
Employees
700
as of 2026-08-03
Market cap
$16.5k
as of 2026-08-03
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$14.2k$14.2k2021
Net income-$1.7M-$1.7M2021
Operating income-$1.7M-$1.7M2021
Total assets$763.7k$763.7k2021
Liabilities$186.4k$186.4k2021
Equity$577.4k$577.4k2021
Revenue trend
FY2019 – FY2021 · USD
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Wuhan General Group (China), Inc.’s revenue?
Wuhan General Group (China), Inc. booked $14.2k in FY2021 revenue, contracting 57% year over year — slower than 83% of Healthcare companies we track, at a -12086.9% net margin.
Peers · Healthcare
Navidea Biopharmaceuticals, Inc.——Nass Valley Gateway Ltd.——Premier Biomedical, Inc.——Cryomass Technologies Inc.——Relmada Therapeutics, Inc.38DThe Greater Cannabis Company, Inc.14DKey facts
CEOJeff Robinson
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersCape Town, NV
ExchangeOTC: WUHN
Employees700
IPO date2006-04-19
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.